title: What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set.
abstract: OBJECTIVE
  Function, patient global assessment, and pain are routinely measured in rheumatoid arthritis (RA) clinical trials. However, other patient-reported outcomes identified as important to patients in qualitative studies, such as fatigue and quality of life, are commonly not included, and modern treatment regimens may have changed patients' expectations of treatment outcomes. Our objective was to elicit patient priority treatment outcomes for pharmacologic interventions since the common use of anti-tumor necrosis factor (anti-TNF) therapy, which will form the basis of a core set of patient priorities to complement existing professional core sets.
  
  
  METHODS
  In-depth interviews were conducted with 23 RA patients, purposively sampled for age, sex, medication (anti-TNF or other disease-modifying antirheumatic drugs), disease severity, and work status. Grounded theory guided iterative data collection and analysis. Coding of the data was peer reviewed. A patient research partner collaborated in the research design and analysis.
  
  
  RESULTS
  Sixty-three different outcomes important to patients were generated from the interviews. Four major categories of patient outcomes from pharmacologic treatments were developed: "RA under control," "Doing things," "Emotional health," and "Coping with illness." The core category (or overall theme) was "Minimizing the personal impact of RA."
  
  
  CONCLUSIONS
  Although the routine outcomes of pain, function, and overall well-being were raised by the patients, they also generated a further 60 important outcomes that they look for from treatment. This difference in perspective may potentially influence treatment decisions. The next step is therefore to use these data to develop a patient core set.
authors.affiliation: University of the West of England and Bristol Royal Infirmary, Bristol, UK. Tessa2.Sanderson@uwe.ac.uk
authors.forename: T
authors.initials: T
authors.lastname: Sanderson
authors.forename: M
authors.initials: M
authors.lastname: Morris
authors.forename: M
authors.initials: M
authors.lastname: Calnan
authors.forename: P
authors.initials: P
authors.lastname: Richards
authors.forename: S
authors.initials: S
authors.lastname: Hewlett
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology; D001294:Attitude to Health; D017281:Cost of Illness; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011788:Quality of Life / Q000523:psychology
chemical_list: D018501:Antirheumatic Agents
references.citation: J Rheumatol. 1993 Mar;20(3):579-81
references.pmid: 8478878
references.citation: Med Decis Making. 2001 Mar-Apr;21(2):113-21
references.pmid: 11310944
references.citation: Arthritis Res Ther. 2006;8(4):R84
references.pmid: 16684371
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Rheumatology (Oxford). 2005 Jan;44(1):105-10
references.pmid: 15381792
references.citation: Ann Rheum Dis. 2009 Feb;68(2):183-90
references.pmid: 18375533
references.citation: J Rehabil Med. 2004 Jul;(44 Suppl):87-93
references.pmid: 15370754
references.citation: Ann Rheum Dis. 2006 Jun;65(6):763-9
references.pmid: 16249225
references.citation: Curr Opin Rheumatol. 2007 Mar;19(2):101-5
references.pmid: 17278922
references.citation: Arthritis Care Res. 1995 Jun;8(2):94-101
references.pmid: 7794992
references.citation: Arthritis Rheum. 1980 Feb;23(2):137-45
references.pmid: 7362664
references.citation: J Rheumatol. 2007 May;34(5):1174-7
references.pmid: 17477482
references.citation: Musculoskeletal Care. 2005;3(3):131-42
references.pmid: 17042002
references.citation: J Rheumatol. 2005 Nov;32(11):2250-6
references.pmid: 16265712
references.citation: Rheumatology (Oxford). 2004 Aug;43(8):1034-8
references.pmid: 15150436
references.citation: Musculoskeletal Care. 2004;2(1):40-50
references.pmid: 17041967
references.citation: J Rheumatol. 1992 Jul;19(7):1031-7
references.pmid: 1512756
references.citation: Arthritis Rheum. 1997 Jul;40(7):1267-74
references.pmid: 9214427
references.citation: Disabil Rehabil. 2001 Nov 10;23(16):706-21
references.pmid: 11732560
references.citation: J Rheumatol. 2003 Apr;30(4):868-72
references.pmid: 12672218
references.citation: J Rheumatol. 2003 Apr;30(4):877-9
references.pmid: 12672220
references.citation: Arthritis Rheum. 1993 Jun;36(6):729-40
references.pmid: 8507213
references.citation: J Rheumatol. 2003 Apr;30(4):880-3
references.pmid: 12672221